Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Molecular targets for the protodynamic action of cis-urocanic acid in human bladder carcinoma cells

Authors: Emilia Peuhu, Aura Kaunisto, Jarmo K Laihia, Lasse Leino, John E Eriksson

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

cis-urocanic acid (cis-UCA) is an endogenous amino acid metabolite capable of transporting protons from the mildly acidic extracellular medium into the cell cytosol. The resulting intracellular acidification suppresses many cellular activities. The current study was aimed at characterizing the molecular mechanisms underlying cis-UCA-mediated cytotoxicity in cultured cancer cells.

Methods

5367 bladder carcinoma cells were left untreated or treated with cis-UCA. Cell death was assessed by measuring caspase-3 activity, mitochondrial membrane polarization, formation and release of cytoplasmic histone-associated DNA fragments, and cellular permeabilization. Cell viability and metabolic activity were monitored by colorimetric assays. Nuclear labelling was used to quantify the effects of cis-UCA on cell cycle. The activity of the ERK and JNK signalling pathways was studied by immunoblotting with specific antibodies. Phosphatase activity in cis-UCA-treated cells was determined by assay kits measuring absorbance resulting from the dephosphorylation of an artificial substrate. All statistical analyses were performed using the two-way Student's t-test (p < 0.05).

Results

Here we report that treatment of the 5637 human bladder carcinoma cells with 2% cis-UCA induces both apoptotic and necrotic cell death. In addition, metabolic activity of the 5637 cells is rapidly impaired, and the cells arrest in cell cycle in response to cis-UCA. Importantly, we show that cis-UCA promotes the ERK and JNK signalling pathways by efficiently inhibiting the activity of serine/threonine and tyrosine phosphatases.

Conclusions

Our studies elucidate how cis-UCA modulates several cellular processes, thereby inhibiting the proliferation and survival of bladder carcinoma cells. These anti-cancer effects make cis-UCA a potential candidate for the treatment of non-muscle invasive bladder carcinoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference De Fabo EC, Noonan FP: Mechanism of immune suppression by ultraviolet irradiation in vivo. I. evidence for the existence of a unique photoreceptor in skin and its role in photoimmunology. J Exp Med. 1983, 158: 84-98. 10.1084/jem.158.1.84.CrossRefPubMed De Fabo EC, Noonan FP: Mechanism of immune suppression by ultraviolet irradiation in vivo. I. evidence for the existence of a unique photoreceptor in skin and its role in photoimmunology. J Exp Med. 1983, 158: 84-98. 10.1084/jem.158.1.84.CrossRefPubMed
2.
go back to reference Norval M, El-Ghorr AA: Studies to determine the immunomodulating effects of cis-urocanic acid. Methods. 2002, 28: 63-70. 10.1016/S1046-2023(02)00210-4.CrossRefPubMed Norval M, El-Ghorr AA: Studies to determine the immunomodulating effects of cis-urocanic acid. Methods. 2002, 28: 63-70. 10.1016/S1046-2023(02)00210-4.CrossRefPubMed
3.
go back to reference Laihia JK, Pylkkänen L, Laato M, Boström PJ, Leino L: Protodynamic therapy for bladder cancer In vitro results of a novel treatment concept. BJU Int. 2009, 104: 1233-1238. 10.1111/j.1464-410X.2009.08611.x.CrossRefPubMed Laihia JK, Pylkkänen L, Laato M, Boström PJ, Leino L: Protodynamic therapy for bladder cancer In vitro results of a novel treatment concept. BJU Int. 2009, 104: 1233-1238. 10.1111/j.1464-410X.2009.08611.x.CrossRefPubMed
4.
go back to reference Laihia JK, Kallio J, Taimen P, Kujari H, Kähäri V-M, Leino L: Protodynamic intracellular acidification by cis-urocanic acid promotes apoptosis of melanoma cells in vitro and in vivo. J Invest Dermatol. advance online publication, 3 June 2010 Laihia JK, Kallio J, Taimen P, Kujari H, Kähäri V-M, Leino L: Protodynamic intracellular acidification by cis-urocanic acid promotes apoptosis of melanoma cells in vitro and in vivo. J Invest Dermatol. advance online publication, 3 June 2010
5.
go back to reference Thangaraju M, Sharma K, Liu D, Shen SH, Srikant CB: Interdependent regulation of intracellular acidification and SHP-1 in apoptosis. Cancer Res. 1999, 59: 1649-1654.PubMed Thangaraju M, Sharma K, Liu D, Shen SH, Srikant CB: Interdependent regulation of intracellular acidification and SHP-1 in apoptosis. Cancer Res. 1999, 59: 1649-1654.PubMed
6.
go back to reference Cosentini E, Haberl I, Pertschy P, Teleky B, Mallinger R, Baumgartner G, Wenzl E, Hamilton G: The differentiation inducers phenylacetate and phenylbutyrate modulate camptothecin sensitivity in colon carcinoma cells in vitro by intracellular acidification. Int J Oncol. 2001, 19: 1069-1074.PubMed Cosentini E, Haberl I, Pertschy P, Teleky B, Mallinger R, Baumgartner G, Wenzl E, Hamilton G: The differentiation inducers phenylacetate and phenylbutyrate modulate camptothecin sensitivity in colon carcinoma cells in vitro by intracellular acidification. Int J Oncol. 2001, 19: 1069-1074.PubMed
7.
go back to reference Gottlieb RA, Nordberg J, Skowronski E, Babior BM: Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification. Proc Natl Acad Sci USA. 1996, 93: 654-658. 10.1073/pnas.93.2.654.CrossRefPubMedPubMedCentral Gottlieb RA, Nordberg J, Skowronski E, Babior BM: Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification. Proc Natl Acad Sci USA. 1996, 93: 654-658. 10.1073/pnas.93.2.654.CrossRefPubMedPubMedCentral
8.
go back to reference Matsuyama S, Llopis J, Deveraux QL, Tsien RY, Reed JC: Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat Cell Biol. 2000, 2: 318-325. 10.1038/35014006.CrossRefPubMed Matsuyama S, Llopis J, Deveraux QL, Tsien RY, Reed JC: Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat Cell Biol. 2000, 2: 318-325. 10.1038/35014006.CrossRefPubMed
9.
go back to reference Juusola P, Minkkinen P, Leino L, Laihia JK: Determination of the dissociation constants of urocanic acid isomers in aqueous solutions. Monatsh Chem. 2007, 138: 951-965. 10.1007/s00706-007-0687-1.CrossRef Juusola P, Minkkinen P, Leino L, Laihia JK: Determination of the dissociation constants of urocanic acid isomers in aqueous solutions. Monatsh Chem. 2007, 138: 951-965. 10.1007/s00706-007-0687-1.CrossRef
10.
go back to reference Donella-Deana A, MacGowan CH, Cohen P, Marchiori F, Meyer HE, Pinna LA: An investigation of the substrate specificity of protein phosphatase 2C using synthetic peptide substrates; comparison with protein phosphatase 2A. Biochim Biophys Acta. 1990, 1051: 199-202. 10.1016/0167-4889(90)90194-I.CrossRefPubMed Donella-Deana A, MacGowan CH, Cohen P, Marchiori F, Meyer HE, Pinna LA: An investigation of the substrate specificity of protein phosphatase 2C using synthetic peptide substrates; comparison with protein phosphatase 2A. Biochim Biophys Acta. 1990, 1051: 199-202. 10.1016/0167-4889(90)90194-I.CrossRefPubMed
11.
go back to reference Daum G, Solca F, Diltz CD, Zhao Z, Cool DE, Fischer EH: A general peptide substrate for protein tyrosine phosphatases. Anal Biochem. 1993, 211: 50-54. 10.1006/abio.1993.1231.CrossRefPubMed Daum G, Solca F, Diltz CD, Zhao Z, Cool DE, Fischer EH: A general peptide substrate for protein tyrosine phosphatases. Anal Biochem. 1993, 211: 50-54. 10.1006/abio.1993.1231.CrossRefPubMed
12.
go back to reference Zhang ZY, Thieme-Selfer AM, Maclean D, McNamara DJ, Dobrusin EM, Sawyer TK, Dixon JE: Substrate specificity of the protein tyrosine phosphatases. Proc Natl Acad Sci USA. 1993, 90: 4446-4450. 10.1073/pnas.90.10.4446.CrossRefPubMedPubMedCentral Zhang ZY, Thieme-Selfer AM, Maclean D, McNamara DJ, Dobrusin EM, Sawyer TK, Dixon JE: Substrate specificity of the protein tyrosine phosphatases. Proc Natl Acad Sci USA. 1993, 90: 4446-4450. 10.1073/pnas.90.10.4446.CrossRefPubMedPubMedCentral
13.
go back to reference Fujiki H, Suganima M: Carcinogenic aspects of protein phosphatase 1 and 2A inhibitors. Prog Mol Subcell Biol. 2009, 46: 221-254. full_text.CrossRefPubMed Fujiki H, Suganima M: Carcinogenic aspects of protein phosphatase 1 and 2A inhibitors. Prog Mol Subcell Biol. 2009, 46: 221-254. full_text.CrossRefPubMed
14.
go back to reference Liu D, Chen Z: The effects of cantharidin and cantharidin derivates on tumour cells. Anticancer Agents Med Chem. 2009, 9: 392-396.CrossRefPubMed Liu D, Chen Z: The effects of cantharidin and cantharidin derivates on tumour cells. Anticancer Agents Med Chem. 2009, 9: 392-396.CrossRefPubMed
15.
go back to reference Rajesh D, Schell K, Verma AK: Ras mutation, irrespective of cell type and p53 status, determines a cell's destiny to undergo apoptosis by okadaic acid, an inhibitor of protein phosphatase 1 and 2A. Mol Pharmacol. 1999, 56 (3): 515-525.PubMed Rajesh D, Schell K, Verma AK: Ras mutation, irrespective of cell type and p53 status, determines a cell's destiny to undergo apoptosis by okadaic acid, an inhibitor of protein phosphatase 1 and 2A. Mol Pharmacol. 1999, 56 (3): 515-525.PubMed
16.
go back to reference Knowles MA, Williamson M: Mutation of H-ras is infrequent in bladder cancer: Confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res. 1993, 53: 133-139.PubMed Knowles MA, Williamson M: Mutation of H-ras is infrequent in bladder cancer: Confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res. 1993, 53: 133-139.PubMed
17.
go back to reference Boulalas I, Zaravinos A, Karyotis I, Delakas D, Spandidos DA: Activation of RAS family genes in urothelial carcinoma. J Urol. 2009, 181: 2312-2319. 10.1016/j.juro.2009.01.011.CrossRefPubMed Boulalas I, Zaravinos A, Karyotis I, Delakas D, Spandidos DA: Activation of RAS family genes in urothelial carcinoma. J Urol. 2009, 181: 2312-2319. 10.1016/j.juro.2009.01.011.CrossRefPubMed
18.
go back to reference Tannock IF, Rotin D: Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989, 49: 4373-4384.PubMed Tannock IF, Rotin D: Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989, 49: 4373-4384.PubMed
19.
go back to reference Arentsen HC, Falke J, Jansen CFJ, Hulsbergen-van de Kaa CA, Laihia JK, Pylkkänen L, Leino L, Oosterwijk E, Witjes JA: Antitumour effects of cis-urocanic acid, an intravesical protodynamic drug, in experimental urothelial cell carcinoma of the bladder. Eur Urol Suppl. 2010, 9: 292- Arentsen HC, Falke J, Jansen CFJ, Hulsbergen-van de Kaa CA, Laihia JK, Pylkkänen L, Leino L, Oosterwijk E, Witjes JA: Antitumour effects of cis-urocanic acid, an intravesical protodynamic drug, in experimental urothelial cell carcinoma of the bladder. Eur Urol Suppl. 2010, 9: 292-
Metadata
Title
Molecular targets for the protodynamic action of cis-urocanic acid in human bladder carcinoma cells
Authors
Emilia Peuhu
Aura Kaunisto
Jarmo K Laihia
Lasse Leino
John E Eriksson
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-521

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine